Good morning, everyone. Welcome to the 2022 Annual General Meeting of Bubs Australia. My name is Dennis Lin, Executive Chair of the company. Before we begin, we would like to acknowledge First Nations people as the traditional custodians of the land on which we work in Australia. We pay our respects to elders past, present, and emerging, and to the youth who are working towards a brighter tomorrow. Today's meeting is being held in person and online via the Computershare meeting platform. This allows shareholders, proxies, and guests to attend the meeting virtually. All attendees can watch a live webcast of the meeting. Shareholders and proxies have the ability to ask questions and submit votes. To commence today's proceedings, our Managing Director and Chief Executive Officer, Kristy Carr, will present an overview of Bubs' journey in FY 2022. Following the CEO address, I will then outline each resolution during the formal business of the meeting and address your questions and comments on the resolutions on which shareholders are voting. Personally, I couldn't be prouder of Bubs Family as they worked tirelessly throughout the year to make the impossible possible against the volatile macro setting. These achievements were recognized earlier this week at the 60th Australian Export Awards, hosted by the Australian Trade and Investment Commission in Parliament House, where Bubs Australia not only won our category, Agribusiness, Food and Beverage, but was also crowned the overall winner for 2022 Australian Exporter of the Year. I will present the resolutions and then open the floor for questions. Online attendees can submit questions at any time. To ask a question, select the Q&A icon. Type your question into the text box. Once you have finished typing, please hit the Send button. Please note that while you can submit questions from now on, I will not address them until the relevant time in the meeting. Please also note that your questions may be moderated or if we receive multiple questions on one topic, amalgamated together. To ask a verbal question, please follow the instructions written below the broadcast. Voting today will be conducted by way of a poll on all items of business. I will shortly open voting for all resolutions. If you are eligible to vote, once voting open, press the Vote icon and all resolutions will be activated with voting options. To cast your vote, simply select one of the options. There is no need to hit a Submit or Enter button as the vote is automatically recorded. You will receive a vote confirmation notification on your screen. You can change your vote up until the time I declare voting closed. I now declare voting open on all items of business. Before closing the meeting, I will also address any general questions related to the business. I would now like to formally introduce your board. In room with me, we have Kristy Carr, Founder and Managing Director. Kristy founded the business in 2006 and is responsible for the brand DNA and authenticity that makes Bubs so special. She leads a team of extremely talented people across all business functions between our Sydney, Melbourne, Shanghai and L.A. offices. We also have Katrina Rathie, our Independent Non-Executive Director. Katrina joined the Bubs board mid last year. Katrina Rathie was Partner in Charge for King & Wood Mallesons Sydney office, and brings 35 years of experience as a leading expert in international IP and a consumer brand lawyer with extensive governance experience. With us online, dialing in from the United States, we have Steve Lin, a Non-Executive Director. Steve is Managing Partner of C2 Capital Partners, a Hong Kong-based investment fund anchored by Alibaba Group. Steve provides the board with industry-leading expertise on growth capital, proprietary insights, and operational support to scale in China. With us in person today is Jay Stephenson, our Company Secretary. Jay has performed this role since our public listing in 2017. Jay is a professional Company Secretary with extensive experience for numerous ASX-listed companies. I would like to introduce our key management personnel. We have Iris Ren, Chief Financial Officer. Iris joined the company in 2017 and has extensive experience in financial advisory and transactions, audit and compliance. We also have Richard Paine, our Chief Operating Officer. Richard is a 30-year veteran in dairy and supply chain operations, including past experiences in key roles at Bega Cheese and Murray Goulburn. Our auditor for financial year 2022, Deloitte, is represented here by Partner Andrew Sung, together with his team, who will be happy to take questions on the financial statements relevant to the audit process. Also present is Carly Lane, a partner from our external lawyers, Ashurst, and Peter Cope, who acts as our in-house General Counsel. I will now hand over to Kristy to present a business update and outline the key elements of our growth strategy to take us forward. Kristy? Thank you, Dennis. At this time last year, we were starting to emerge from the impacts of the pandemic and learning how to manage the consequent disruptions to business norms. In a testament to Bubs' renowned resilience and agility, we stand here today in a position to report record revenues and earnings for financial year 2022, driven by innovation and margin- accretive growth across Australia, China, as well as our accelerated market entry into the United States. FY 2022 delivered record revenue and earnings with high growth in all key product segments and new markets. Our domestic market share continued to grow ahead of the category to reach all-time highs and deliver record market share gains. We experienced strong growth momentum across our China business with the re-engineered and resurgent model in conjunction with our strategic partner, AZ Global. Additionally, in the last quarter of FY 2022, we significantly accelerated our access into the United States. Our work over the previous 12 months meant that we were well-positioned to respond quickly to satisfy the U.S. regulatory requirements and ensure that Bubs Australia was one of the first global manufacturers to participate in the Biden administration's Operation Fly Formula initiative to assist American families during the infant formula shortage crisis. By the end of FY 2022, Bubs was ranged in over 6,000 leading grocery department and pharmacy retail stores across 42 states in America with a clear permanent pathway to market access and significant level of consumer brand awareness. Since June, we have shipped just over 1 million tins of Bubs infant formula to the United States. The speed and success of our entry into the U.S. led to a AUD 63 million oversubscribed capital raising to support our accelerated expansion, including building inventory and in-market capability to expand the company's presence in the U.S. A portion of these proceeds will enable the company to triple our capacity of our infant formula processing and canning facility in Dandenong South, Victoria to meet our future growth in forecasted demand. Planning and procurement for a second high-speed capacity line is underway. Installation is scheduled as planned for late calendar year 2023. Cumulatively, the steps we have taken to diversify and expand our business delivered a positive underlying EBITDA accompanied by group-wide margin gains from optimizing our product and channel mix. Innovation is inherent in Bubs' DNA and a key driver to our high-growth strategy. With the launch in FY 2022 of Bubs Supreme A2 beta-casein protein in our most profitable business segment, we are now able to cater for a more significant share of the addressable infant formula and toddler milk market, thereby strengthening our position in the total category to build widespread recognition of the Bubs brand as synonymous with clean, high-quality infant nutrition. Bubs Supreme is our most advanced formulation to date, enriched with higher levels of Omega-3 plant-based DHA and Omega-6 ARA, a synbiotic blend of pre and probiotics, Lutein for normal eye health support, as well as vitamins and minerals for optimal nutrition. Bubs Supreme has been awarded the Clean Label Purity Award, meaning it is free from GMOs, artificial colors and preservatives, Maltodextrin, corn syrup, palm oil, and over 400 contaminants, including heavy metals. The launch of this new product line means Bubs master brand now competes in the three fastest-growing segments of the infant formula category: goat, organic, and A2 protein. The same Australian labor products that are sold here in Coles, Woolworths, and Chemist Warehouse are exported to both China and the U.S., enhancing efficiencies in our procurement, supply chain, and manufacturing processes. Strategically, we advanced two major regulatory milestones this year that will have a material long-term influence on the business. Firstly, we accelerated access into the United States with our early acceptance by the U.S. Food and Drug Administration, or FDA, in the last quarter of FY 2022 to permit the import of Bubs infant formula products under the Enforcement Discretion Policy. Further advancing our United States market access ambitions. In this quarter, we lodged a letter of intent with the FDA under its transition plan for continued enforcement discretion for all six of Bubs infant formula products, and are committed to fully complying with the applicable requirements for a permanent regulatory authorization by October 2025. This means we will be able to continue to import our full range of Australian labeled formula products and remain on shelf without disruption while we complete the remaining regulatory requirements. Secondly, we advanced plans to establish manufacturing capability in China in a joint venture with an established China-based infant formula manufacturer to attain approval from the State Administration for Market Regulation, or SAMR, for Bubs Chinese labeled goat milk infant formula products, which would subsequently provide the company market access to China's general trade in mother and baby bricks and mortar stores for the first time. If the application is approved, the existing brand slot will be rebranded as Bubs and be compliant with the new GB regulatory requirements, which come into effect in February 2023. Only a select few multi-billion-dollar multinational companies around the world have the same level of regulatory access to both China and the US, the two largest infant formula markets in the world. This is a true reflection of Bubs' agility to navigate and penetrate unique growth markets that are not readily accessible to others. FY 2022 gross revenues were more than double that of FY 2021 at AUD 104.2 million, at a 123% increase on prior year. This growth trajectory was bolstered by Bubs infant formula growing at 177% on prior year and China revenue growth increasing 166% year-on-year. This scalability allowed us to report for our first full year of underlying EBITDA profit of AUD 4.8 million. These strong financial outcomes were particularly pleasing given the lingering impacts of COVID-19, supply chain disruption, inflation, and the global economic uncertainty. Group branded margins improved with our infant formula portfolio showing material margin gains. Gross margins increased significantly over the year to 32% for the group, and product margin for Bubs goat milk infant formula increased to 40%. This was driven primarily by increased scale, a growing proportion of sales derived from higher-margin infant formula, optimization of product and channel mix, improved supply-side economics derived from our vertically integrated manufacturing model. Emerging from the pandemic, diversification has remained at the forefront of our strategic focus. Importantly, the success of our portfolio expansion means we are no longer dependent on goat milk infant formula sales into China for margin growth. We were very pleased with the diversified product and channel mix in FY 2022 and anticipate continued optimization in the diversified spread of revenue contribution in FY 2023 and beyond. This brings us to our master growth strategy, which is founded on the key values of being a trusted source of nutrition with strong Clean Label attributes underpinned by our expertise in specialty dairy. Operationally, we will leverage Bubs' portfolio expansion with the premium segments in which we operate remaining in high growth, as well as our strategic alliances in key markets with the highest growth category potential. Over the last 12 months, we have become more acutely aware of the evolving desires of consumers and their purchase behavior. This is particularly pronounced in the USA, where parents have become accustomed to making online purchases and conducting significant research online. At the same time, they continue to desire access to infant formula in everyday bricks and mortar stores, especially premium formulation that are more akin to those here in Australia and in Europe. We observed similar phenomenon in China, which was the genesis for our manufacturer to consumer, otherwise known as M to C model, which will now give us visibility of knowing where each tin of infant formula is sold to the final consumer. This level of visibility has not been achieved by any brand in the past, as it requires a vertically integrated brand manufacturer to partner deeply with the channels as we have done with AZ Global. Over the next year and beyond, we will take these learnings and focus on precision performance growth. Precision requires access to data for analysis so that we know where to invest each marketing dollar to obtain the best return, as well as topics that are top of mind for consumers and channel partners. Having seen the growth momentum that is now being achieved in the M2C through targeted investments, we are confident of creating material growth momentum in China long term. In the USA, we have achieved the challenging task of having stocks in now over 6,500 bricks and mortar stores. Through performance and growth marketing, a term that refers to significantly growing revenue using targeted digital marketing strategies. We are also confident of building on our existing consumer base in the U.S. and creating our own Bubs communities for years to come. Having worked through the largest infant nutrition markets in the USA and China, it has also provided us with a fresh lens of how we may be able to grow our market share at a faster rate here in Australia, with refreshed brand identities that stay true to our values through positive and supportive discussion with parents about their baby feeding journeys. In Australia, we will protect and grow our share in our home market, where we are still remain the fastest growing infant formula manufacturer and continue to outperform the category in compounding value growth. In FY 2022, domestic revenue increased by 17% over the previous year and contributed 16% to our total group revenue. Retail scan data shows Bubs as the clear challenger brand, outperforming the category with high scan sales growth and market share gain, recording new market share peaks in Chemist Warehouse, Woolworths and Coles. Bubs sales growth was more than twice of any of its competitors and now stands at 4.9% share of the total domestic market. Bubs is proudly the number one goat formula brand in Australia, with 56% share of the total category and number two organic formula brand here in Australian retailers. Whilst industry-wide headwinds were prevalent throughout FY 2022, consumer demand for Bubs products remains strong and the market potential provides the company with our greatest opportunity for growth. After the initial COVID-led disruption caused by border closures, we worked closely with our strategic partner, AZ Global, to re-engineer how our products were routed through the Daigou channel. This alliance and pivot in strategy led to rapid revenue growth in FY 2022 and has enabled the direct delivery from within China via reseller recruitment for Bubs brand representatives. During the first quarter of FY 2023, Bubs led the launch of the enhanced M2C model, powered by proprietary software applications developed by AZ Global. The new M2C model provides us with real-time, end-to-end product visibility and sell-through data for Bubs products. It enables participants to become brand ambassadors and benefit in introducing products to their respective communities in a low touch manner without working capital needs and with consistent brand marketing content provided by Bubs. As well as all products being appropriately tax cleared in preparation for China's impending Golden Tax System Phase IV, which is due to officially commence in early 2023. The company expects to engage in an aggressive expansion plan in second half of FY 2023 that will provide a new level of corporatized brand distribution of infant formula in China. The United States is the second largest infant formula market globally, valued at $5.6 billion. Up until now, it is, for all intents and purposes, been a closed market tightly held by a select few multinationals. However, the weakness of this concentrated capacity was exposed when the market leader had to suspend operations due to a contamination scare, triggering a dangerous shortage that left retailer shelves empty for months and widespread panic among new parents. Bubs was the first manufacturer in the world to respond to Biden administration's call for international assistance, demonstrating our agility and long term commitment to the American market as our next growth horizon. In May, the company was permitted to import all 6 Bubs infant formula products under the Enforcement Discretion Policy, which led to the U.S. government chartering 6 747 cargo planes to deliver over half a million tins of Bubs infant formula under Operation Fly Formula. Speed to market has unlocked enormous value as we have rapidly scaled our retail footprint, which now stands at over 6,500 stores across 42 states, including the largest four retailers of infant formula in the U.S., namely Target, Walmart, Albertsons, Safeway and Kroger, as well as health food retailers like Whole Foods, baby retailers like buybuy BABY, and e-commerce marketplaces like Amazon. We are confident we can satisfy the requirements for permanent market access under the FDA Guidance for Industry Infant Formula Transition Plan to continue supplying all Bubs infant formula products to the U.S. on a permanent basis. In summary, Bubs' team have demonstrated resilience, agility and strategic focus throughout financial year 2022, delivering a strong strategic scorecard and record performance results. We entered FY 2023 with a diversified product portfolio in our most profitable business segment. A new growth horizon with the accelerated market access in the U.S.A. A re-engineered business model in China that provides us with end-to-end channel visibility. Permanent regulatory pathways for full access to the world's two largest infant formula markets. A robust balance sheet to increase our manufacturing capacity and support our future growth plans. Looking to the future, management continues to focus on delivering our operational action plan for building on our strategic foundations to counter unfavorable macro forces impacting our business. We remain focused on our long-term high growth agenda and delivering on our vision to make Bubs a leading global infant formula brand. Short-term revenue growth is likely to be constrained by the transition to the new M2C model in China and sell-through of the initial high volume pipe- fill orders to retailers in the U.S. Due to this phasing, we expect the first half of 2023 revenue to be largely consistent with prior year, with strong growth momentum to be realized in the second half of FY 2023. Overall, we expect FY 2023 to deliver healthy growth in revenue, further improvements to our product margin. The business will increase its investment in resources and marketing, support the growth in demand. In the second half of FY 2023, the business will also commence an ERP upgrade project, which will bring further efficiency and automation to daily business operations. With the business achieving critical scale, our focus will be on margin accretion from farm to consumer and earnings growth. Despite the ongoing macro challenges and softer start to the financial year than planned, we remain confident in achieving our long-term growth ambitions. Finally, I would like to take this opportunity to thank The Bubs Family wherever they are around the world, for the way they are able to rise to the challenges of responding to the significant macro forces during the year. I would also like to particularly highlight the superhuman effort the team demonstrated in delivering on our promise to American parents during the crisis, with the delivery of 1 million tins of formula to date. We couldn't have achieved what we have this year without their loyalty, dedication, and entrepreneurial spirit. Congratulations to all of you on winning the 2022 Exporter of the Year award earlier this week. I would also like to extend my gratitude to our shareholders and strategic partners for your ongoing support of Bubs' journey to becoming a global dairy company and category leader in infant nutrition. That concludes the FY 2022 business update. I'll now hand back to Dennis for the formal business of the meeting. Thank you, Kristy. Since by now you will have received the notice of meeting, with your permission, I will take these as read. I'm advised by our Company Secretary that this meeting is properly constituted, that the proxies have been inspected, and all those validly lodged have been accepted, and that the necessary quorum of shareholders is present. It being the annual general meeting of the company, I'm obliged to table the financial statements, Directors' Report, and Auditors' Report for the company for the year ended June 30th, 2022. I now table those documents which are contained in the Annual Report, which is available on the company investor website. In the presence of the company's auditors, if anyone would like to address any questions or comments on the financial statements, I'm happy to receive them at the relevant time for questions in our meeting. I now turn to the resolutions for today's meeting. On the screen, you will see there are now nine resolutions before the meeting today. The nine resolutions before the meeting today are: one, the adoption of remuneration report. Two, the re-election of myself as a director. Resolution three, approval of issue of securities under the Employee Share Rights Plan. Resolution four, approval of issue of share rights to Executive Chair, myself, Dennis Lin. Resolution five, approval of issue of share rights to Managing Director, Kristy Carr. Resolution six, ratification of prior issue of shares. Resolution seven, amendment to constitution. Eight, appointment of new auditor. Finally, nine, increase in non-executive directors' fee pool. Resolution one is a non-binding ordinary resolution. Resolution one is a special resolution which will be passed if at least 75% of the votes cast by shareholders entitled to vote on the resolution are voted in favor. All other resolutions are ordinary resolutions that will be passed if more than 50% of the votes cast by shareholders present or by proxy are voted in favor. I confirm that all resolutions will be held by poll. I will now proceed to put forward the resolutions to shareholders. Resolution one, the adoption of the remuneration report, which is a non-binding resolution. The motion is that for the purpose of Section 250, sub-subsection one of the Corporations Act, and for all other purposes, approval is given for the adoption of the remuneration report as contained in the company's annual financial report for the financial year ended June 30th, 2022. The proxies are outlined on the screen. Ladies and gentlemen, at a listed company's annual general meeting, a resolution that the remuneration report be adopted must be put to shareholders. Please note that the vote on this resolution is advisory only and does not bind the directors or the company. Resolution number two being the re-election of myself. As this resolution relates to myself, I will now pass the chair to my fellow director, Katrina Rathie. Katrina? Thank you, Dennis. The motion is that for the purpose of clause 14.2 of the Constitution, ASX Listing Rule 14.4, and for all other purposes, Mr. Dennis Lin, who retires as a director by rotation and being eligible is re-elected as a director. The proxies are as outlined on the screen, and I'll now pass back to Dennis. Thank you, Katrina. Moving on to resolution number three. Approval of issue of securities under Employee Share Rights Plan. The motion is that for the purpose of ASX Listing Rule 7.2, exception 13B, and for all other purposes, approval is given by the company to issue equity securities under the Employee Incentive scheme titled Employee Share Rights Plan on the terms and conditions set out in the explanatory statement. The proxies are outlined on the screen. Moving on to resolution number four, approval of issue of share rights to myself. As the next resolution relates to me, I will now pass the chair back to my fellow director, Katrina. The motion is that for the purpose of ASX Listing Rule 10.14 and for all other purposes, approval is given for the company to issue 606,502 share rights to Dennis Lin or his nominees under the Employee Share Rights Plan on the terms and conditions set out in the explanatory statement. The proxies are outlined on the screen. I'll now pass back to Dennis. Thank you, Katrina. Moving on to Resolution number five, approval of issue of share rights to Managing Director Kristy Carr. The motion is that for the purpose of ASX Listing Rule 10.14 and for all other purposes, approval is given for the company to issue 1,091,703 share rights to Kristy Carr or her nominees under the Employee Share Rights Plan on the terms and conditions set out in the explanatory statement. The proxies are outlined on the screen. Moving on to Resolution number six, ratification of prior issue of shares. The motion is that for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders ratify the allotment and issue of 63,374,717 shares to eligible institutional investors on the terms and conditions set out in the explanatory statement. The proxies are outlined on the screen. Moving to Resolution number seven, amendment to constitution. The motion is that for the purposes of Section 136(2) of the Corporations Act, and for all other purposes, approval is given by the company to amend its constitution to include new provisions around the use of technology by the company, as set out in item seven of the explanatory statement. The proxies are outlined on the screen. Resolution number eight, Appointment of new auditor. The motion is that subject to asset consent of being received by the company for Deloitte Touche Tohmatsu to resign as auditor for the purpose of Section 327B(1)(b) of the Corporations Act, and for all other purposes, KPMG, having been nominated by a shareholder and having consented in writing to act, be appointed as auditor of the company. The proxies are outlined on the screen. Finally, Resolution number nine. Increase in non-executive directors' fee pool. The motion is that for the purposes of clause 14.7 and 14.8 of the company's constitution, ASX Listing Rule 10.17, and for all other purposes, approval is given for the company to increase the total aggregate fixed sum per annum to be paid to non-executive directors by AUD 200,000 to normal and AUD 500,000. The proxies outlined on the screen. We will now address any questions from our shareholders. For the questions from the floor, please raise your hand if you have a question. Jay Stephenson, I believe you have several questions as well. I think what we might do is we might take any questions from the floor first. Jay Stephenson, if you could actually help me by, I guess, just letting me know the question and also the, you know, to the extent possible, the identity of the person asking the question as well. All right. Firstly, any questions from the floor? No? If you do think of any at any time, please feel free to raise your hand. Jay, did you want to actually go through the questions that have come through online? Yep. there's three questions, they're all from the same shareholder, Mr. Dennis Lin. First question is: It seems that China is adhering to its COVID zero policy. Assuming if the restrictions remain in place for the rest of 2023, even into the first half of 2024 financial year, will the operation in China alone, cost and revenue, expect to be at least break even or even net profit positive? Okay. Jay, thank you very much for that, and thank you for Mr. Lin for sending through the question. I think it's fair to say that the last three years have already been quite extraordinary for us in dealing with the COVID environment. You know, we respect any country in the way they choose to, I guess, govern. Certainly in relation to China, the COVID zero policy is, first of all, no different to what we have been dealing with over the last two to three years. I think as you can see from FY 2022, that China was a significant contributor as a market for us, both in terms of revenue as well as the bottom line. Certainly this is a business that does not rely on China, as we have mentioned before, that we now have the U.S. and Australia that are also contributing materially to the business. Certainly China is a material part of the business that we operate in. I would simply say that, you know, as we sort of move into the remainder of FY 2023 and FY 2024, the policies in China, you know, do not, I guess, worry us because it's no different to what we have worked on over the last three years. Certainly it remains a risk that we continue to monitor and observe. Thank you, Jay. Second question from Mr. Lin is: Mr. Lin previously said that he expects net cash positive is likely to occur in 2023. Has his view changed since the last shareholder meeting? Okay. No, thank you. Thank you Mr. Lin, for that question. The we do have, I guess, the discipline that is required by the ASX, and I think it's a good one for us to actually report our cash flow on a quarterly basis. Therefore, you will have seen that during the first quarter, because we were required to actually hold additional inventory for the impending growth that our cash was down during the first quarter. Certainly we are expecting our second half to through significant growth and through being able to actually maintain our product margin for that to be offset. Jay? Okay. Third question from Mr. Lin: Has Bubs considered a dividend scheme as a form of returning benefit back to its shareholders once net operating income turns more consistently positive? Thank you Mr. Lin, for that question. The answer is most certainly. You know, we are a high growth company, and as a result, our focus has been on attaining scale at the revenue line and not doing it at all costs, which is why we continue to talk about gross margin and product margin to ensure that the growth is profitable. Because having sustainable gross margin is really the underlying engine that will allow us to actually reward our shareholders, you know, through the consideration of a dividend policy. I can certainly assure, I guess, our shareholders that it is always a conversation that we have around the board table around how we may be able to actually act in the best interest of shareholders, whether that would be to reinvest the cash for growth, or to return that to shareholders in time. Okay. Are there any other questions? There's no further questions. Okay, no worries. Do we have any questions from the floor? Please. Thank you. First of all, I'd like to congratulate the team on the speed with which you've been able to satisfy the requirements in the U.S. and ship the quantity within such a short period of time. Compliments to the management on that one. My question is: When will the cash generation from the operations of the company be sufficient to support the growth of the company in the future? Are there any plans for further capital raisings on the basis of your current growth plans? Thank you. For those that are online, I might just repeat the question if it's okay. The question was, does the company envisage the existing balance sheet to be sufficient to take the company to a cash flow positive and a self-generating scenario? Whether we have any additional capital raising plans. I will firstly say that we do operate in a very volatile environment, therefore I always caution that to be an issue. At the same time, I can assure you that the board and management are 100% focused on making sure that we have plenty of firepower within our existing balance sheet to take the company forward to that position without any further capital raise. Okay. Any other questions from the floor? No? Do we have any audio questions, Jay? There are no audio questions. Okay, no worries. I always like to give people another 10, 15 seconds just in case they have last-minute questions. Okay. On the basis that we have no further questions, that concludes our discussion on the various items of business. Now, in a couple of minutes, I will close the voting system. Please ensure that you have cast your vote on all resolutions. I will now pause to allow you time to finalize those votes. There will be 60 seconds for those that are online. Thank you.